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Abstract 
Myocardial ischemia/reperfusion (IR) injury is a major cause of death worldwide and remains 
a disease for which current clinical therapies are strikingly deficient. While the production of 
mitochondrial reactive oxygen species (ROS) is a critical driver of tissue damage upon 
reperfusion, the precise mechanisms underlying ROS production have remained elusive. 
More recently it has been demonstrated that a specific metabolic mechanism occurs during 
ischemia that underlies elevated ROS at reperfusion, suggesting a unifying model as to why 
so many different compounds have been found to be cardioprotective against IR injury. This 
review will discuss the role of the citric acid cycle intermediate succinate in IR pathology 
focussing on the mechanism by which this metabolite accumulates during ischemia and how 
it can drive ROS production at complex I via reverse electron transport (RET). We will then 
examine the potential for manipulating succinate accumulation and metabolism during IR 
injury in order to protect the heart against IR damage and discuss targets for novel 
therapeutics designed to reduce reperfusion injury in patients.   
 
Introduction 
Acute myocardial infarction (AMI) occurs when the complete occlusion of a coronary artery, 
for example due to rupture of an unstable atherosclerotic plaque, results in a region of 
myocardial ischemia. AMI is a major cause of death worldwide and is the primary cause of 
chronic heart failure (CHF). Despite a marked improvement in outcomes post-AMI in recent 
decades, due largely to the introduction of early reperfusion therapies, currently one quarter 
of patients will die or develop heart failure within one year (1). Irreversible myocardial injury 
progresses with increasing duration of ischemia, therefore the rapid restoration of blood flow 
to the ischemic area, via primary percutaneous coronary intervention (PPCI) or thrombolysis, 
is essential so as to salvage viable myocardium. Reperfusion itself however can 
paradoxically induce cardiomyocyte death independent of the ischemic episode by a process 
known as reperfusion injury (2). Indeed, experimental studies have shown that interventions 
applied at reperfusion can achieve an approximate reduction of 50% in final infarct size (3). 
Decreasing reperfusion injury is therefore a key target in the battle to preserve cardiac 
function in AMI patients. Despite this clear need, there is currently no effective therapy for 
the prevention of reperfusion injury available, and the translation of drugs from experimental 
studies to clinical trials has been disappointing (4–6). In this review we will discuss the role 
of mitochondrial reactive oxygen species (ROS) in the pathology of ischemia/reperfusion (IR) 
injury and how the citric acid cycle (CAC) intermediate, succinate, is emerging as a key 
driver of ROS production at reperfusion. From this we will go on to highlight the 
cardioprotective potential of intervening in succinate accumulation and metabolism in an 
attempt to identify novel targets for future therapies against reperfusion injury. 
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Ischemia/reperfusion injury: reactive oxygen species and complex I 
An extraordinary amount of research has been carried out in order to understand the 
mechanisms by which the myocardium is damaged during IR injury, (3,7,8). In a normoxic 
heart 60-90% of the acetyl-CoA supplied to the CAC originates from the β-oxidation of fatty 
acids, with a smaller contribution from glycolysis and lactate oxidation (9). During acute 
ischemia, the lack of oxygen results in a switch to anaerobic glycolysis resulting in the build-
up of lactate and a decrease in intracellular pH (10,11). ATP depletion and acidosis drive 
cytosolic Na+ accumulation via the sodium/hydrogen exchanger (NHE) and as a 
consequence excess Na+ is extruded, in exchange for calcium (Ca2+), through the reverse 
action of the plasma membrane Na+/Ca2+, exchanger (NCX) (12). During ischemia, the usual 
Ca2+ uptake by the sarcoplasmic reticulum Ca2+-ATPase (SERCA) is prevented due to the 
decline in ATP resulting in cytosolic Ca2+ overload (13,14). Furthermore, there is an 
accumulation of metabolic end-products, including hypoxanthine, xanthine and succinate 
(15–17). Reperfusion and subsequent re-oxygenation of the cell results in the rapid 
restoration of the mitochondrial membrane potential (Dψm) providing a large driving force for 
Ca2+ uptake into mitochondria via the mitochondrial calcium uniporter (MCU) (18). 
Reperfusion also leads to a large burst of ROS as oxygen reacts with leaked electrons to 
form superoxide (19). Within minutes of reperfusion, intracellular pH returns to normal due to 
the extrusion of protons by the NHE and the inhibitory effect on the mitochondrial 
permeability transition pore (mPTP) is released (11,20). Stimulated by the rise in 
mitochondrial ROS and Ca2+, opening of the mPTP is induced resulting in a complete 
collapse of Dψm, cytochrome c release and the activation of necrotic and apoptotic signalling 
cascades leading to cardiomyocyte death (21,22). Beyond triggering the onset of mPTP 
formation, excessive ROS can also induce tissue dysfunction directly through the 
peroxidation of lipids, oxidation of DNA and activation of matrix metalloproteinases (23,24) 
(Fig. 1). IR injury is therefore a highly complex process and one for which many aspects 
have yet to be fully characterised. Even so, it is clear that the large burst of ROS produced at 
reperfusion is incompatible with cell survival and is a critical factor in the pathogenesis of IR 
injury. ROS consequently constitute a potentially powerful pharmacological target in 
protecting the myocardium against infarction and antioxidant therapy, which inhibits or 
delays oxidative damage, is especially appealing. The development of effective antioxidants 
has however proven difficult, with blanket strategies, such as vitamin C and E, proving 
ineffective at improving clinical outcome (5). These disappointing results may in part be due 
to the precise molecular mechanisms responsible for ROS production remaining elusive with 
numerous sites having been implicated (25–27). The mitochondrial electron transport chain 
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has been recognized as a significant source of cellular ROS with complexes I (28–30) and III 
(25,31) identified as the predominant sites of superoxide production. The physiological 
relevance of ROS produced by complex III to in vivo scenarios remains uncertain given its 
requirement for conditions in which the ubisemiquinone radical is stable at the Qo site, most 
often achieved through its artificial inhibition by antimycin A (32). Moreover the complex III 
inhibitor myxothiazol, which inhibits ROS generation from the complex, was found to not 
decrease IR injury implying its limited involvement in the detrimental ROS burst at 
reperfusion (33). Interestingly however, complex III generated ROS has been implicated in 
the physiological signalling that occurs during volatile anesthestic and hypoxic pre-
conditioning (33,34). Therefore in the context of IR, while a contribution to ROS by complex 
III should not be dismissed, under physiological conditions its involvement in ROS-mediated 
damage at reperfusion is thought to be lower than that of complex I (32,35). Indeed there is 
now an extensive body of work pointing towards mitochondrial complex I as a chief source of 
ROS at reperfusion with the inhibition of complex I during IR found to protect against IR 
injury (30,36). Complex I is the primary point of electron entry into the respiratory chain and 
is responsible for the oxidation of NADH and the extrusion of protons out of the 
mitochondrial matrix. In the context of IR, complex I undergoes an active/de-active transition 
in which during ischemia it converts to a ‘de-active’ state before being rapidly re-activated 
upon reperfusion (37,38). Importantly it has been shown that the inhibition of this re-
activation, particularly through the reversible S-nitrosation of key cysteines, prevents ROS 
production and protects the myocardium against infarction (39–42) and long-term 
dysfunction (43). These findings suggest that in contrast to a largely unregulated response, a 
specific metabolic process occurs during ischemia priming the heart for ROS production 
through complex I at reperfusion which will be discussed in further detail below (17).  
 
Succinate accumulation is a metabolic signature of ischemia 
The heart is highly energy demanding and capable of utilising a variety of substrates, 
including free fatty acids, glucose, lactate and amino acids, for the production of ATP. The 
heart is also highly dependent on the constant delivery of oxygen, and disruption of this 
process, for example during ischemia or hypoxia, causes profound disturbances in 
myocardial metabolism (15,16,44). During ischemia, the lack of blood flow results in the loss 
of ATP, lactate accumulation and the build-up of metabolites including those within the CAC, 
purine nucleotide degradation pathways and those involved in fatty acid and amino acid 
metabolism (15,45,46). Despite metabolic adaptations to both myocardial hypoxia and 
ischemia being studied at length, the potential link to the generation of deleterious ROS 
during IR injury has been for the most part overlooked. Comparative metabolomics recently 
revealed that across multiple tissues three metabolites demonstrated conserved 
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accumulation during ischemia (17). Of these, two were components of the purine 
degradation pathway, hypoxanthine and xanthine. While both hypoxanthine and xanthine 
contribute to xanthine oxidase-derived generation of hydrogen peroxide, they interact with 
xanthine oxidase at the plasma membrane and do not contribute to mitochondrial ROS 
production (47). The third metabolite and sole mitochondrial component to show significant 
accumulation was the CAC intermediate and complex II substrate, succinate (17). 
Elucidation of the phenomenon of succinate accumulation is certainly not new. Hochachka et 
al. first demonstrated elevations in succinate during anaerobosis in their work on diving 
mammals in 1975 (48,49). Since then, ischemic succinate build-up has been observed in 
hypoxic rabbit papillary muscles (15), hypoxic isolated rat cardiomyocytes (50) and in the 
isolated mouse heart (51). Succinate accumulation can therefore be considered a universal 
signature of ischemia and an attractive candidate for a potential electron source for ROS 
production at reperfusion. The exact role of ischemic succinate however and the 
physiological basis behind its striking accumulation remains to be fully elucidated. Original 
propositions as to its function included forming part of an extra-glycolytic source for energy in 
situations of low nutrient and oxygen availability, therefore increasing tolerance to long-term 
anaerobosis (49). Wiesner et al. hypothesised that the production of succinate improved 
cytosolic redox state and thus was somehow beneficial during hypoxia (52). Indeed, 
improvements in cardiac function during hypoxia have been reported in isolated rat hearts 
perfused with potential precursors of succinate formation (53,54). In recent years the role of 
succinate has also expanded well beyond its action within the CAC and the electron 
transport chain with new roles discovered in inflammation (55) and GPCR stress-signalling 
(56). How these functions relate to the accumulation of succinate in anaerobic conditions 
remains to be investigated. Importantly, succinate can also drive the highest rate of 
mitochondrial ROS production in isolated mitochondria (32,35,57) in a process known as 
reverse electron transport (RET), and this will be discussed in detail later in the review.  
 
Succinate is rapidly oxidised at reperfusion 
As the burst of mitochondrial ROS production occurs within the first few minutes of 
reperfusion (19,42), it follows that ischemic metabolites fuelling ROS production should also 
be oxidised rapidly over a similar time-frame. Consistent with this hypothesis, succinate is 
abruptly lost from the tissue upon reperfusion, returning to pre-ischemic levels after only a 
few minutes (17,51). This is likely due to the rapid oxidation of succinate to fumarate by 
complex II in the mitochondrial matrix making succinate a highly attractive candidate for 
driving reperfusion-mediated ROS production. It should be noted that succinate in the 
mitochondria rapidly equilibrates with that in the cytosol via the mitochondrial dicarboxylate 
carrier (DIC) and may also be lost from the cell as a result of cell membrane disruption (58). 
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Consequently loss of a proportion of this metabolite through leakage upon reperfusion 
cannot be discounted (16). Despite this, it remains likely that a significant proportion of 
ischemic succinate is available to supply complex II-mediated oxidation upon reperfusion 
and recent work in which the inhibition of complex II slowed myocardial succinate loss at 
reperfusion now supports this (59). 
 
Ischemic succinate is produced by the reverse action of complex II 
In mammalian tissues, succinate is usually generated by the CAC via the oxidation of 
carbons from both glucose and fatty acids as a result of glycolysis and β-oxidation. 
Succinate can however also be produced from several mitochondrial reactions originating 
from amino acids (49). The first involves the ready conversion of glutamate to α-
ketoglutarate (α-KG) by transamination. α-KG is then converted to succinate via succinyl-
CoA, generating energy as GTP through standard operation of the CAC (15). This 
anaplerotic reaction not only acts to maintain levels of CAC intermediates but has been 
suggested to contribute significantly to total anaerobic maintenance of the mitochondrial 
membrane potential, although this remains contentious (60,61). The conversion of α-KG to 
succinyl-CoA is however strongly unfavourable due to the high NADH/NAD+ ratio that occurs 
during ischemia and previous work has found no evidence of the conversion of α-KG to 
succinyl-CoA in the hypoxic isolated rat heart (50). Therefore while some contribution from 
α-KG to ischemic succinate cannot be entirely ruled out, it is likely to be less than that via 
other pathways. The other reaction involves the ‘fumarate reductase’ system. This system is 
composed of complex I and the reverse activity of complex II where succinate acts as the 
electron acceptor from reduced Coenzyme Q (CoQH2). This reverse action of complex II has 
been proposed to enable proton pumping by complex I even in the absence of oxygen and 
the maintenance, to some extent, of the proton electrochemical potential gradient needed for 
ATP synthesis (62). Moreover, the fumarate required as substrate for this reaction can be 
generated from pathways such as the malate-aspartate shuttle (MAS) and purine nucleotide 
cycle (PNC). Indeed work by our group and collaborators recently demonstrated that these 
two key pathways did contribute to ischemic succinate formation in both the isolated mouse 
heart and in vivo mouse model of IR injury (17). By inhibiting each pathway selectively 
during ischemia, by means of the inhibitors 5-Aminoimidazole-4-carboxamide ribonucleotide 
(AICAR) and aminooxyacetate (AOA) respectively, we significantly attenuated ischemic 
succinate levels in vivo (17). Moreover treating mice during ischemia with dimethyl malonate, 
a cell-permeable form of the complex II inhibitor malonate, ischemic succinate accumulation 
was similarly prevented (17). Interestingly these results suggest that CoQH2, generated by 
complex I, is oxidised by complex II acting in reverse with fumarate acting as an electron 
acceptor resulting in the build-up of succinate.  
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Succinate drives ROS production at reperfusion through RET at complex I 
At reperfusion, the large burst of mitochondrial superoxide that occurs appears to originate 
largely from mitochondrial complex I (30,42,63). While there are a number of ROS sources 
that may contribute to IR injury, including NADPH oxidases and xanthine oxidase, activation 
of these processes is thought to occur later in pathology and are thus not a focus of this 
review.  
Complex I can produce superoxide via two potential mechanisms. The first occurs in 
the presence of a high matrix NADH/NAD+ ratio in which a reduced flavin mononucleotide 
site reacts with oxygen to produce superoxide. This process occurs during conventional 
forward electron transport and is promoted by the complex I Coenzyme Q (CoQ) site 
inhibitor rotenone (32). Given that rotenone has been shown to be protective against 
oxidative damage during IR (36,63), it is unlikely that superoxide produced via this 
mechanism contributes significantly to reperfusion-induced ROS production. The second 
mechanism occurs via RET in which a highly reduced CoQ pool in conjunction with a 
maximal ∆ψm and low rate of ATP synthesis forces electrons from the reduced CoQ pool 
back through complex I (32,57). Notably this phenomenon has been observed in isolated 
mitochondria respiring on high concentrations of succinate and is associated with the 
greatest rate of mitochondrial ROS production known to occur (32). Despite RET being 
observed in brain, liver and heart mitochondria (64,65), it has generally been assumed to be 
solely an in vitro phenomenon of unknown physiological significance with the concentration 
of succinate in tissues being significantly lower than what is commonly used in in vitro 
experiments to evoke RET-mediated ROS (5-10 mM). However, recent work has shown that 
conditions at reperfusion are in fact sufficient to support RET with evidence of increased 
levels of ischaemic succinate and accelerated re-polarization of ∆ψm at reperfusion (17). In 
support of this mitochondrial ROS was tracked in a primary isolated rat cardiomyocyte model 
of simulated IR using the fluorescent probe dihydroethidium (DHE) (17). Upon reperfusion, 
DHE was rapidly oxidised consistent with increased superoxide production following the re-
introduction of oxygenated buffer. Inhibiting complex II during ischemia with dimethyl 
malonate reduced reperfusion-mediated DHE oxidation. In contrast, the addition of dimethyl 
succinate, a cell-permeant derivative of succinate, to cardiomyocytes to artificially increase 
ischemic succinate levels significantly enhanced DHE oxidation at reperfusion. Critically, the 
selective inhibition of complex I with rotenone or MitoSNO abolished both endogenous and 
exogenous succinate-driven ROS production. These results are in accordance with previous 
work in which complex II inhibitors, including (dimethyl) malonate, diazoxide and atpenin A5 
(AA5), have all been shown to reduce ROS production in vitro when administered prior to 
ischemia (17,66,67). Inhibiting succinate accumulation in vivo with dimethyl malonate 
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similarly abolished mitochondrial ROS production, as determined by the mass spectrometry 
ROS probe MitoB, and superoxide-mediated oxidative damage at reperfusion (17). These 
data therefore indicate that ischemic succinate levels control the extent of reperfusion ROS 
through complex I during IR injury both in vitro and in vivo.  
 
A unifying theory of ROS production upon reperfusion 
The recently defined metabolic transitions that occur within mitochondria during AMI offer a 
potential solution to the long sought mechanism for ROS production during IR injury. 
Readers are directed to a recent review in which this mechanism is described in more detail 
(68). During ischemia there is a build-up of succinate, as fumarate is converted to succinate 
via reverse action of complex II. The ATP/ADP ratio progressively decreases and 
accumulated AMP is further metabolised within the PNC as well as degraded to 
hypoxanthine and xanthine. Upon reperfusion the re-introduction of oxygen results in the 
rapid oxidation of the huge pool of electrons stored as succinate at complex II, resulting in a 
near maximal ∆ψm via complexes III and IV and a highly reduced CoQ pool (68). Adenine 
nucleotides depleted during ischemia and restoration to normoxic levels can take a 
significant amount of time (69,70). As a result, ATP synthesis is compromised at reperfusion 
and the reduced CoQ pool is maintained due to complex III being unable to consume all of 
the electrons supplied to the pool by succinate oxidation. The excess electrons are therefore 
forced back through complex I resulting in a large burst of ROS (Fig. 1). In conjunction with 
Ca2+ overload, ROS triggers the opening of the mPTP and activation of the cells apoptotic 
machinery resulting in cardiomyocyte death. Inhibiting succinate build-up during ischemia 
with dimethyl malonate prevents ROS production from complex I by RET (Fig. 2). This 
unifying theory provides a possible explanation for why such a wide array of compounds, 
including complex I and II inhibitors and uncouplers, are cardioprotective and offers a 
potentially novel therapeutic target to help reduce infarct size during IR.  
 
Preventing succinate accumulation or oxidation as a therapeutic target for 
cardioprotection 
Ischemic succinate levels appear to control the extent of ROS at reperfusion. This suggests 
that manipulation of the pathways that increase succinate during ischemia, as well as those 
that oxidise it at reperfusion, should affect the degree of IR injury. In agreement with this the 
reversible inhibition of complex II with dimethyl malonate during ischemia and the 
attenuation of succinate accumulation significantly reduced infarct size in vivo (17). Indeed 
malonate, as well has other complex II inhibitors, have been previously shown to reduce 
ROS generation in isolated mitochondria (67,71) with AA5 protecting against IR injury in the 
isolated rat heart when given prior to ischemia (72). A recent study has also demonstrated 
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dimethyl malonate to be cardioprotective in the isolated mouse heart when infused prior to 
global ischemia (73). The exact mechanism by which this class of respiratory inhibitors 
protects against tissue damage however remains somewhat contentious with conflicting 
evidence with regards to the significance of the proposed mitochondrial ATP-sensitive 
potassium channel (mKATP) (74,75). The mKATP has been implicated as a critical factor in 
ischaemic preconditioning-mediated cardioprotection (76). mKATP has however also been 
functionally linked to complex II with significant pharmacological overlap demonstrated 
between the two mitochondrial components. Activators of mKATP, such as diazoxide, have 
been shown to inhibit complex II activity (77,78) while inhibitors of complex II, including 
malonate, can similarly activate mKATP (75). Low concentrations of diazoxide, sufficient to 
activate mitochondrial potassium flux, however have no discernible effect on complex II 
activity and mKATP specific actions can be inhibited by the mKATP blocker, 5-
hydroxydecanoate (79). Moreover, recent work supports a role for the renal outer medullary 
potassium channel (ROMK) as a pore-forming subunit for the mKATP channel (80). 
Therefore, while the precise molecular composition of mKATP remains to be fully elucidated 
and there are clear pharmacological parallels between the channel and complex II, it is likely 
to be distinct molecular entity. Whether dimethyl malonate is affecting mKATP function during 
IR injury however remains unclear. Given that the restoration of succinate levels 
exogenously abolished dimethyl malonate induced cardioprotection, data do indicate that 
protection resulted solely from the blunting of succinate accumulation (17). The potential for 
off-target effects unrelated to the inhibition of RET however, cannot be entirely ruled out.  
 While inhibiting succinate accumulation during ischemia may be highly useful in 
situations of known ischemia, including elective surgery and organ transplantation, it is not 
clinically appropriate during an AMI where patients arrive at hospital with succinate already 
accumulated in the ischemic tissue. The usefulness of malonate in vivo as a chronic 
prophylactic treatment may also be limited by its effect on other organ systems with 
prolonged administration leading to striatal lesions that mimic Huntington’s disease (81). It is 
therefore essential to determine if dimethyl malonate is equally effective at ameliorating 
cardiac injury when used later in IR, such as just prior to reperfusion. Succinate 
accumulation during ischemia only becomes pathological upon its rapid oxidation at 
reperfusion in which it drives RET-mediated ROS production through complex I. By 
suppressing succinate oxidation at the point of reperfusion through complex II inhibition and 
allowing a ‘gradual wake-up’ of mitochondrial metabolism, compounds including dimethyl 
malonate could be potentially valuable cardioprotectants. Support for this has recently been 
demonstrated in the isolated mouse heart when the administration of malonate at 
reperfusion only reduced infarct size and improved ventricular function (59). Moreover the 
authors directly attributed cardioprotection to the inhibition of succinate re-oxidation at 
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reperfusion and the prevention of ROS production (59). Malonate is therefore a potentially 
valuable tool for preserving mitochondrial function in a variety of settings and the model 
outlined here provides an avenue for the development of novel interventions against the 
generation of excessive mitochondrial ROS in a range of pathologies in which IR injury is 
implicated.  
 
Other potential therapeutic targets 
 
While the production and metabolism of ischaemic succinate is an important therapeutic 
target when targeting RET-mediated ROS, it is by no means the only target that should be 
considered. Downstream of succinate oxidation the inhibition of the transition of complex I to 
its active state at reperfusion will also prevent ROS production and has been shown 
frequently to protect against IR injury (28,41,42). Furthermore a critical condition required for 
the occurrence of RET is the generation of a near-maximal ∆ψm by the activity of complexes 
III and IV in combination with limited flux through the ATP synthase. Therapies that 
manipulate any of the numerous components involved could potentially have a beneficial 
effect by preventing RET induced ROS production. These would include the prevention of 
rapid ∆ψm repolarisation using inhibitors of complexes III and IV, such as myxothiazol (33) 
and hydrogen sulphide (82), dissipation of ∆ψm by mitochondrial uncouplers (83), and 
compounds that preserve or increase ADP content.  
 
Future Perspectives 
Despite considerable progress in treating AMI, there is a clear need for a novel secondary 
approach that can be applied in conjunction with current reperfusion therapy to protect the 
myocardium from infarction and achieve the full potential benefits of myocardial reperfusion. 
Succinate-mediated ROS production is emerging as a leading candidate for intervention 
during IR injury. Whether the inhibition of succinate-mediated ROS plays a significant role in 
other established cardioprotective mechanisms such as ischemic pre- and post-conditioning 
remains to be determined. The most important study however that remains to be carried out 
is to determine whether succinate accumulates in clinical settings of IR. 
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Figure 1. Schematic illustrating the main components of ischemia/reperfusion injury. 
During myocardial ischemia, the lack of oxygen causes a switch to anaerobic respiration, 
resulting in the production of lactate and a drop in intracellular pH. This disrupts ion 
haemostasis resulting in Na+ and Ca2+ overload. The low pH also prevents the opening of 
the mPTP. Oxidative phosphorylation is inhibited and NADH/NAD+ ratio increases. ATP 
stores are depleted as ATP is hydrolysed to AMP by ATP synthase in order to maintain ∆ψm. 
During reperfusion, the electron transport chain is re-activated and restored resulting in the 
normalisation of intracellular pH and ∆ψm and a large influx of Ca2+ into the mitochondrion. 
Complex I is rapidly reactivated resulting in a large burst of ROS. Opening of the mPTP is 
induced resulting in the collapse of the ∆ψm, the triggering of apoptosis and cardiomyocyte 
death. OXPHOS = oxidative phosphorylation. ∆ψm = mitochondrial membrane potential.  
 
 
21 
 
III IV
V
ADP + Pi ATP
Fumarate
Succinate
NAD+
NADH
H+ H+
Matrix
IMS
H+ H+
QH2 Cyto C
Q
Ischemia
PNC MAS
ADP
↑AMP
INACTIVE
↓O2
↓Δψm
III IV
V
¯ ADP + Pi ATP
Succinate
Fumarate
NAD+
NADH
H+ H+
Matrix
IMS
H+ H+
QH2
Q
Reperfusion
­Δψm
­ ROS
TCA 
Cycle
H+ H+
O2 H2O
H+ H+
II
I
II
I
Cyto C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. ROS production by succinate-driven reverse electron transport during 
ischemia/reperfusion in the heart.  During ischemia, the purine nucleotide cycle (PNC) 
and malate aspartate shuttle (MAS) supply fumarate to complex II. Complex II acts in 
reverse by using CoQH2 produced by complex I to reduce fumarate to succinate. ATP is 
hydrolysed to AMP due to insufficient ATP production. At reperfusion, oxygen is restored 
and the excess succinate is rapidly metabolised by complex II in its forward direction. A 
delay in the regeneration of ADP from AMP limits flux through ATP synthase, complex III 
and complex IV. This prevents complex III from using the ubiquinol generated by complex II 
as the membrane potential increases. Electrons are therefore forced back through complex I 
such that it runs in reverse generating large amounts of superoxide. Cyto C = cytochrome c. 
IMS = intermembrane space.  
